The kallikrein-kinin pathway is dysregulated in HAE1

Uncontrolled plasma kallikrein leads to excessive bradykinin production2

Uncontrolled plasma kallikrein leads to excessive bradykinin production, which can cause HAE attacks
Uncontrolled plasma kallikrein leads to excessive bradykinin production, which can cause HAE attacks

Figure adapted from Valerieva et al, Bender et al, and Csuka et al.3-5
C1-INH=C1 esterase inhibitor; cHMWK=cleaved high molecular weight kininogen; FXII=factor XII; FXIIa=factor XIIa; HMWK=high molecular weight kininogen; PKa=activated plasma kallikrein.

An established mAb targeting the inhibition of plasma kallikrein to reduce the release of bradykinin1

TAKHZYRO provides targeted inhibition of plasma kallikrein, a critical regulator of bradykinin, known to cause HAE attacks1

TAKHZYRO's mechanism of action on plasma kallikrein
TAKHZYRO's mechanism of action on plasma kallikrein

Figure adapted from Valerieva et al, Bender et al, and Csuka et al.3-5
C1-INH=C1 esterase inhibitor; cHMWK=cleaved high molecular weight kininogen; FXII=factor XII; FXIIa=factor XIIa; HMWK=high molecular weight kininogen; PKa=activated plasma kallikrein.

See efficacy and safety across all 3 studies

Explore the results of the HELP study, the HELP open-label extension study, and the SPRING study.

EXPLORE TAKHZYRO DATA

References: 1. Takhzyro. Prescribing information. Dyax Corp; 2023. 2. Banerji A, Busse P, Shennak M, et al. N Engl J Med. 2017;376(8):717-728. doi:10.1056/NEJMoa1605767. 3. Valerieva A, Longhurst HJ. Front Allergy. 2022;3:952233. doi: 10.3389/falgy.2022.952233. 4. Bender L, Weidmann H, Rose-John S, et al. Front Immunol. 2017;8:1115. doi:10.3359/fimmu.2017.01115. 5. Csuka D, Veszeli N, Imreh É, et al. Orphanet J Rare Dis. 2015;10:132. doi:10.1186/s13023-015-0351-5.